Pre-emptive genotyping for pharmacogenomic risk - establishing a benchmark

Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality in health care. In the US alone, an estimated two million serious ADRs occur annually, causing over 100,000 deaths per year. Based on these estimates, ADRs are the 4th leading cause of death ahead of pulmonary disease, diabetes, AIDS, and pneumonia. The percentage of hospital admissions due to ADRs in some countries exceeds 10%. 

Due to the magnitude of this problem healthcare organizations and pharmaceutical companies worldwide are developing major initiatives to reduce the cost and impact of ADRs. Pre-emptive pharmacogenomic genotyping is a pivotal new approach using genetic data to gain valuable insights into metabolic status to better understand the cause of adverse events. 

Ulrich Broeckel, MD and Chief, Section of Genomic Pediatrics at the Medical College of Wisconsin, is a leader in pharmacogenomics research and will share his experience in establishing a new benchmark for pre-emptive genotyping for pharmacogenomics.

During this session you will learn:

• How translational clinical researchers gain valuable insight into an individual’s ability to process drugs known to be actionable and where high, moderate, low, preliminary and unknown evidence exists
• Why genotyping of highly predictive markers in genes including GSTM1, CYP1A2, CYP2D6, CYP2B6, CYP2A6, SULT1A1, CYP2C19, and CYP2C8 that are in highly homologous regions is important 
• How copy number variation (CNV) analysis for important ADME genes is integrated into the system 

For Research Use Only. Not for use in diagnostic procedures.